ABVC Biopharma shares jump on drug license deal

ABVC Biopharma

01/08/2023 15:03

** Shares in ABVC Biopharma Inc  ABVC.O  up 40.0% at $3.49 after
announcing licensing deal bringing it possible aggregate income
of $20 mln for ABV-1504 for Major Depressive Disorder (MDD) and
ABV-1505 for Attention-Deficit/Hyperactivity Disorder (ADHD)
    ** Under agreement, Xinnovation Therapeutics Co., Ltd will
have exclusive rights to develop, manufacture, market, and
distribute ABVC's MDD and ADHD drugs in Chinese market, to bear
costs for clinical trials, product registration in China.
    ** ABVC, which had hit a record intraday low of $2.40 on
Monday, had spiked as high as $18.70 on Jan 5 after ending 2022
at $6.25 







 (Reporting By Sinéad Carew)
 ((sinead.carew@thomsonreuters.com; +13322191897;))